Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Mai 2015 07:30 ET | Quelle: REGENXBIO Inc.

REGENXBIO Secures $70.5 Million in a Mezzanine Financing

ROCKVILLE, Md., May 20, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the successful completion of a heavily oversubscribed $70.5 million...
28. April 2015 09:00 ET | Quelle: REGENXBIO Inc.

Luke M. Beshar Appointed to REGENXBIO Board of Directors

ROCKVILLE, Md., April 28, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that Luke M. Beshar has been appointed to its board of directors...
23. April 2015 08:00 ET | Quelle: REGENXBIO Inc.

REGENXBIO and Dimension Therapeutics Add Development of Treatments for Two Metabolic Diseases to Exclusive License Agreement

ROCKVILLE, Md., April 23, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has added the indications of ornithine transcarbamylase...
08. April 2015 09:00 ET | Quelle: REGENXBIO Inc.

REGENXBIO Licenses Key Technologies From University of Pennsylvania and University of Minnesota for the Development of Treatments for MPS I and MPS II

WASHINGTON, April 8, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into separate license and research agreements with...
21. Januar 2015 07:30 ET | Quelle: REGENXBIO Inc.

REGENXBIO Raises $30 Million in Series C Financing

WASHINGTON, Jan. 21, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the completion of a $30 million Series C financing. Venrock and Brookside...
25. November 2014 09:00 ET | Quelle: REGENXBIO Inc.

REGENXBIO to Present at 26th Annual Piper Jaffray Healthcare Conference

WASHINGTON, Nov. 25, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that Ken Mills, President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray...
18. November 2014 09:00 ET | Quelle: REGENXBIO Inc.

Dr. James M. Wilson Joins REGENXBIO as Chief Scientific Advisor

WASHINGTON, Nov. 18, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that James M. Wilson, M.D., Ph.D. has been named its Chief Scientific Advisor, effective immediately. Dr. Wilson is also...
28. Oktober 2014 09:00 ET | Quelle: REGENXBIO Inc.

REGENXBIO Appoints Dr. Stephen Yoo as Chief Medical Officer

WASHINGTON, Oct. 28, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced the appointment of Stephen Yoo, M.D. as Chief Medical Officer, effective immediately. Dr. Yoo will oversee the development...
29. September 2014 16:30 ET | Quelle: REGENXBIO Inc.

REGENXBIO's NAV(R) Technology Demonstrates Correction of Cardiovascular Symptoms of MPS I in Animal Model

WASHINGTON, Sept. 29, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that gene transfer mediated by REGENXBIO's NAV® AAV8 vectors resulted in sustained serum α-L-iduronidase (IDUA)...
27. August 2014 06:30 ET | Quelle: REGENXBIO Inc.

Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS

Results support REGENX's plans to advance gene therapies for MPS I and MPS II into human clinical trials WASHINGTON, Aug. 27, 2014 (GLOBE NEWSWIRE) -- REGENX Biosciences, LLC today announced...

Vorherige Seite

Nächste Seite